MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharmaceutical and Biotech Sectors to Drive Investments in the Asia-Pacific Healthcare Industry Finds Frost & Sullivan - Digital technology advancements and medical tourism enhance growth opportunities in the region - Frost.com
Pharmaceutical and Biotech Sectors to Drive Investments in the Asia-Pacific Healthcare Industry Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Singapore, Singapore, 2019/04/25 - Digital technology advancements and medical tourism enhance growth opportunities in the region - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The higher demand for services and improved quality of care has been attracting significant global investments to the Asia-Pacific healthcare industry.

The pharmaceutical and biotech sectors will generate almost a third of the revenue in 2019, led by cell therapy, high-end devices manufacturing, and drug discovery and development outsourcing.

The market is expected to register a year-on-year growth rate of 7.2 percent in 2019, with China and Japan contributing almost 66 percent of the total revenues. There will also be a 15 percent increase in digital technology investments, which translates to opportunities worth US$13 billion. The need to manage the cost, aging population, and quality of care will especially drive the adoption of digital pathology and eClinical platforms for clinical studies in advanced economies such as Australia, China, Japan, and Singapore.

"The digital transformation of care delivery models towards a personalized and outcome-based treatment paradigm will be a major driver of investments,” said Shalani Andria, Consultant, Transformational Health, Asia-Pacific.

"On the back of this digitization drive, the medical tourism industry is expected to grow and boost demand for patient-centric care products by 20 percent," she explained.

Frost & Sullivan’s recent analysis, Asia-Pacific Healthcare Industry Outlook, 2019, highlights the key market trends and provides strategic recommendations to healthcare vendors. It will help vendors align their strategies with market demand and develop innovative solutions and products that will help them make the most of the market opportunities.

"Digital Transformation in APAC will lead to an opportunity of US$13 billion in 2019. Digital pathology and e-clinical platforms for clinical studies are the hot areas for investment in 2019," noted Andria.

"Technologies that aid in the better prediction and management of revenue cycles, especially for high-risk patient populations, will have a white space opportunity," she added.

In the highly complex and varied Asia-Pacific market, growth opportunities exist in:

• Australia and New Zealand: There is a vast market for integrated Continuous Diagnostics and Mitigation (CDM) programs.
• China: It is anticipated to contribute more than 20 percent of the total regional healthcare revenue in 2019 due to aggressive policies to support medical device and pharmaceutical markets, and heavy investments in AI.
• India: The country is likely to experience more than 30 percent and 15 percent growth in the pharmaceutical and homecare markets, respectively, fueled by the Digital India and Make in • India initiatives, and FDI inflows.
• Japan: It is expected to revolutionize regenerative medicine and become first country in the world to use Embryonic Stem (ES) cells for medical treatments.
• South Korea: It is working on developing a robust clinical-trial environment for medical devices and pharmaceuticals with the aim of becoming a global clinical trial hub.
• ASEAN: Favorable government policies will boost medical tourism and medical-device manufacturing by 15 percent.

Asia-Pacific Healthcare Industry Outlook, 2019 is part of Frost & Sullivan’s global Life Sciences Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Asia-Pacific Healthcare Industry Outlook, 2019 / P3AF-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharmaceutical and Biotech Sectors to Drive Investments in the Asia-Pacific Healthcare Industry Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Melissa Tan - Frost.com 
+65 6890 0926 melissa.tan[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years
GE Healthcare and World Courier Collaborate to Drive Commercialization of Cell and Gene Therapies
Nektium Pharma Commended by Frost & Sullivan for Introducing Zynamite® - A Novel Natural Extract with Ergogenic and Nootropic Properties
Trial Finds Patients Receiving CroFab® Antivenom Less Likely To Use Opioids for Pain Control
ZAGENO Earns Acclaim from Frost & Sullivan for its Unifying Digital Life Sciences Platform
Veeva Vault CDMS Selected for Vivozon’s VVZ-149 Studies

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Inkwood Research

Visit  Limelon Advertising, Co.





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)